Glu-urea-Glu-NHS ester is a functionalized small-molecule targeting ligand precursor designed based on PSMA (Prostate-Specific Membrane Antigen). This molecule features a Glu-urea-Glu core pharmacophore and incorporates an N-hydroxysuccinimide (NHS ester) active ester group, enabling covalent conjugation with molecules containing primary amine groups. It is used for the construction of PSMA-targeting probes, radionuclide theranostic agents, and functionalized nano-delivery systems.
I. Basic Information
| Item | Content |
|---|---|
| Product Abbreviation | Glu-urea-Glu-NHS ester |
| CAS Number | 1228927-36-3 |
| Molecular Formula | C₁₈H₂₅N₅O₉ |
| Molecular Weight | 455.42 |
II. Structural Characteristics and Mechanism of Action
1. Glu-urea-Glu Targeting Structure – Recognizing the PSMA Target
The Glu-urea-Glu structure is derived from the classic PSMA-targeting ligand pharmacophore design, connecting two glutamate groups via a urea linkage, enabling specific interactions with the active region of PSMA.
PSMA is highly expressed on the surface of prostate cancer cells, making this structure suitable as a PSMA-targeting ligand for constructing diagnostic and therapeutic molecules with recognition capability.
2. NHS Active Ester – Enabling Molecular Conjugation
The NHS ester active group introduced at the molecular terminus can undergo amidation reactions with primary amine groups on proteins, peptides, fluorescent dyes, chelators, PEG chains, and nanomaterial surfaces, facilitating the connection between the ligand and functional molecules.
3. Small-Molecule Ligand Platform – Supporting Theranostic Development
As a modular connecting unit, Glu-urea-Glu-NHS ester can be further combined with different functional moieties, such as radionuclide chelators, imaging groups, or drug carriers, to achieve expanded PSMA-targeting functionality.
III. Main Applications
1. Development of PSMA-Targeting Radionuclide Drugs
Glu-urea-Glu-NHS ester can be used to conjugate metal chelators such as DOTA and NOTA, further constructing PSMA-targeting radionuclide theranostic molecules for nuclear medicine imaging and therapeutic research.
2. Construction of PSMA-Targeting Fluorescent Probes
By coupling with amino-containing molecules such as FITC and Cy-series fluorescent dyes, PSMA-targeting fluorescent probes can be prepared for cellular imaging and target site studies.
3. Construction of Targeted Nano-Delivery Systems
Leveraging the reactivity of the NHS ester, Glu-urea-Glu can be conjugated to the surface of liposomes, polymeric nanoparticles, and other carriers to achieve PSMA-targeting functionalization modification.
4. Bioconjugation and Molecular Probe Development
This product can serve as a PSMA-targeting connecting module, combining with proteins, peptides, biotin, and other functional molecules for the construction of multifunctional bioprobes.
IV. Related Radiopharmaceutical Precursor Products
| Product Name | Target | CAS # |
|---|---|---|
| JMV594 | GRPR | 202344-21-6 |
| AE105 | UPAR | 254729-66-3 |
| Cyclo(-RGDfK) | αvβ3 | 161552-03-0 |
| NODAGA-LM3 | SSTR | 1415238-78-6 |
| Cys-LT7 | TfR | 1254540-73-2 |
| Satoreotide | SSTR | 1801415-23-5 |
| AMTG-DA1 | GRPR | 3109994-12-6 |
| IL4RPep-1 | IL-4 | 1900734-29-3 |
| Octreotide | Integrin | 83150-76-9 |
| AB-3PRGD2 | Integrin | 2416165-76-7 |










